Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences, an eyecare technology company listed on Nasdaq under the symbol SGHT, has announced its participation in the Morgan Stanley Global Healthcare Conference in New York City. The management will engage in a fireside chat scheduled for September 13, 2022, at 7:20 AM ET. Investors can access a live and archived webcast of the discussion through the 'Investors' section of their website. The company focuses on innovative solutions to improve patient care for eye diseases, including its OMNI® Surgical System for glaucoma and TearCare® System for dry eye disease.
- None.
- None.
MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
Sight Sciences’ management is scheduled to participate in a fireside chat Tuesday, September 13, 2022, at 7:20am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a trademark of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
What is the purpose of Sight Sciences' participation in the Morgan Stanley Global Healthcare Conference?
When will Sight Sciences participate in the fireside chat at the conference?
How can I access the webcast of Sight Sciences' fireside chat?
What innovative products does Sight Sciences focus on?